drugset / Trial / NCT01679340
A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery
RandomizedParallel-groupOpen-labelPrevention
Summary
To investigate the efficiency and safety of SOX or SP adjuvant chemotherapy to phase II and III gastric cancer patients after D2 surgery. If SOX is equal to SP in efficiency and less toxicity.
Timeline
- Start
- 2011-04
- Primary completion
- 2018-03
- Completion
- 2018-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Oxaliplatin | Small molecule | 65 mg/m2 | Intravenous |
| Subject | S-1 | Small molecule | 80 mg/m2 | Oral |